Search Results - "Kündgen, A"

Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells by Geyh, S, Öz, S, Cadeddu, R-P, Fröbel, J, Brückner, B, Kündgen, A, Fenk, R, Bruns, I, Zilkens, C, Hermsen, D, Gattermann, N, Kobbe, G, Germing, U, Lyko, F, Haas, R, Schroeder, T

“…Ineffective hematopoiesis is a major characteristic of myelodysplastic syndromes (MDS) causing relevant morbidity and mortality. Mesenchymal stromal cells…”
Get full text

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features by Gaidzik, V I, Teleanu, V, Papaemmanuil, E, Weber, D, Paschka, P, Hahn, J, Wallrabenstein, T, Kolbinger, B, Köhne, C H, Horst, H A, Brossart, P, Held, G, Kündgen, A, Ringhoffer, M, Götze, K, Rummel, M, Gerstung, M, Campbell, P, Kraus, J M, Kestler, H A, Thol, F, Heuser, M, Schlegelberger, B, Ganser, A, Bullinger, L, Schlenk, R F, Döhner, K, Döhner, H

“…We evaluated the frequency, genetic architecture, clinico-pathologic features and prognostic impact of RUNX1 mutations in 2439 adult patients with…”
Get full text

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study by Platzbecker, U, Braulke, F, Kündgen, A, Götze, K, Bug, G, Schönefeldt, C, Shirneshan, K, Röllig, C, Bornhäuser, M, Naumann, R, Neesen, J, Giagounidis, A, Hofmann, W-K, Ehninger, G, Germing, U, Haase, D, Wermke, M

Get full text

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO) by Nagel, Gabriele, Weber, D., Fromm, E., Erhardt, S., Lübbert, M., Fiedler, W., Kindler, T., Krauter, J., Brossart, P., Kündgen, A., Salih, H. R., Westermann, J., Wulf, G., Hertenstein, B., Wattad, M., Götze, K., Kraemer, D., Heinicke, T., Girschikofsky, M., Derigs, H.G., Horst, H. A., Rudolph, C., Heuser, M., Göhring, G., Teleanu, V., Bullinger, L., Thol, F., Gaidzik, V. I., Paschka, P., Döhner, K., Ganser, A., Döhner, Hartmut, Schlenk, R. F.

“…We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry. Adult…”
Get full text

Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure by Wattad, M, Weber, D, Döhner, K, Krauter, J, Gaidzik, V I, Paschka, P, Heuser, M, Thol, F, Kindler, T, Lübbert, M, Salih, H R, Kündgen, A, Horst, H-A, Brossart, P, Götze, K, Nachbaur, D, Köhne, C-H, Ringhoffer, M, Wulf, G, Held, G, Salwender, H, Benner, A, Ganser, A, Döhner, H, Schlenk, R F

“…We evaluated the impact of salvage regimens and allogeneic hematopoietic cell transplantation (allo-HCT) in acute myeloid leukemia (AML) with induction…”
Get full text

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study by Germing, U, Lauseker, M, Hildebrandt, B, Symeonidis, A, Cermak, J, Fenaux, P, Kelaidi, C, Pfeilstöcker, M, Nösslinger, T, Sekeres, M, Maciejewski, J, Haase, D, Schanz, J, Seymour, J, Kenealy, M, Weide, R, Lübbert, M, Platzbecker, U, Valent, P, Götze, K, Stauder, R, Blum, S, Kreuzer, K-A, Schlenk, R, Ganser, A, Hofmann, W-K, Aul, C, Krieger, O, Kündgen, A, Haas, R, Hasford, J, Giagounidis, A

“…Myelodysplastic syndromes (MDS) with del(5q) are considered to have a benign course of the disease. In order to address the issue of the propensity of those…”
Get full text

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia by Gaidzik, V I, Weber, D, Paschka, P, Kaumanns, A, Krieger, S, Corbacioglu, A, Krönke, J, Kapp-Schwoerer, S, Krämer, D, Horst, H-A, Schmidt-Wolf, I, Held, G, Kündgen, A, Ringhoffer, M, Götze, K, Kindler, T, Fiedler, W, Wattad, M, Schlenk, R F, Bullinger, L, Teleanu, V, Schlegelberger, B, Thol, F, Heuser, M, Ganser, A, Döhner, H, Döhner, K

“…We investigated the prognostic impact of minimal residual disease (MRD) monitoring in acute myeloid leukemia patients harboring DNA methyltransferase 3A-…”
Get full text

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification by Nachtkamp, K., Strupp, C., Vukelja, M., Kasprzak, A., Haase, D., Ganster, C., Hildebrandt, B., Betz, B., Giagounidis, A., Aul, C., Blum, S., Hofmann, W. K., Pfeilstöcker, M., Valent, P., Lübbert, M., Seidl, M., Rudelius, M., Stauder, R., Krieger, O., Götze, K. S., Bobak, J., Kündgen, A., Schulz, F., Dietrich, S., Kobbe, G., Gattermann, N., Germing, U.

Get full text

Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias by Schuler, E, Schroeder, M, Neukirchen, J, Strupp, C, Xicoy, B, Kündgen, A, Hildebrandt, B, Haas, R, Gattermann, N, Germing, U

“…Highlights • We showed that proliferative CMML types do worse as compared to dysplastic types. • Progression rates of CMML with <5% blasts are lower as…”
Get full text

Risk assessment in chronic myelomonocytic leukemia (CMML) by Germing, U, Kündgen, A, Gattermann, N

“…The clinical course of chronic myelomonocytic leukemia (CMML) is extremely variable, and disease progression can occur at any time from diagnosis. Median…”
Get full text

Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes by Kasprzak, A., Nachtkamp, K., Kondakci, M., Schroeder, T., Kobbe, G., Kündgen, A., Kaivers, J., Rautenberg, C., Haas, R., Gattermann, N., Bonadies, N., Germing, U.

“…The European Leukemia Net (ELN) guidelines for treatment of myelodysplastic syndromes (MDS) connect heterogeneous MDS subgroups with a number of therapeutic…”
Get full text

Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) by GERMING, U, HILDEBRANDT, B, STAUDE, R, GIAGOUNIDIS, A. A. N, STRUPP, C, KÜNDGEN, A, MUELLER, T, HAAS, R, GATTERMANN, N, AUL, C, PFEILSTÖCKER, M, NÖSSLINGER, T, VALENT, P, FONATSCH, C, LÜBBERT, M, HAASE, D, STEIDL, C, KRIEGER, O

“…The international prognostic scoring system (IPSS) is considered the gold standard for risk assessment in primary myelodysplastic syndromes (MDS). This score…”
Get full text

Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients by Platzbecker, U, Al-Ali, H K, Gattermann, N, Haase, D, Janzen, V, Krauter, J, Götze, K, Schlenk, R, Nolte, F, Letsch, A, Ottmann, O G, Kündgen, A, Lübbert, M, Germing, U, Wermke, M, Reinhard, H, Weiss, C, Lieder, K, Ehninger, G, Leismann, O, Giagounidis, A

Get full text

Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group by Jahn, N, Agrawal, M, Bullinger, L, Weber, D, Corbacioglu, A, Gaidzik, V I, Schmalbrock, L, Thol, F, Heuser, M, Krauter, J, Göhring, G, Kündgen, A, Fiedler, W, Wattad, M, Held, G, Köhne, C-H, Horst, H-A, Lübbert, M, Ganser, A, Schlenk, R F, Döhner, H, Döhner, K, Paschka, P

Get full text

P772: PROGNOSTIC IMPACT OF DISEASE‐RELATED RISK FACTORS AND TREATMENT APPROACHES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS) by Lesch, C., Kündgen, A., Nachtkamp, K., Kasprzak, A., Strupp, C., Rudelius, M., Gattermann, N., Kobbe, G., Hildebrandt, B., Germing, U.

Get full text

P589: AGE AND AGE‐ADAPTED RISK FACTORS HIGHLY INFLUENCE SURVIVAL PROBABILITY IN AML PATIENTS – A RETROSPECTIVE ANALYSIS by Nachtkamp, K., Zahner, C., Fricke, A., Ulrych, T., Schulz, F. I., Kündgen, A., Jäger, P. S., Kobbe, G., Germing, U.

Get full text

Transfusion Need and Comorbidities are Independent Prognostic Parameters in Low Risk MDS Patients by Neukirchen, J, Strupp, C, Schuler, E, Zimmermann, E, Kündgen, A, Haas, R, Germing, U

Get full text

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia by Jaramillo, S, Benner, A, Krauter, J, Martin, H, Kindler, T, Bentz, M, Salih, H R, Held, G, Köhne, C-H, Götze, K, Lübbert, M, Kündgen, A, Brossart, P, Wattad, M, Salwender, H, Hertenstein, B, Nachbaur, D, Wulf, G, Horst, H-A, Kirchen, H, Fiedler, W, Raghavachar, A, Russ, G, Kremers, S, Koller, E, Runde, V, Heil, G, Weber, D, Göhring, G, Döhner, K, Ganser, A, Döhner, H, Schlenk, R F

“…The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC…”
Get full text

The IPSS-R has prognostic impact in untreated patients with MDS del(5q) by Kaivers, J., Lauseker, M., Hildebrandt, B., Fenaux, P., Pfeilstöcker, M., Valent, P., Platzbecker, U., Latagliata, R., Oliva, E.N., Xicoy, B., Götze, K., Ganster, C., Haase, D., Bug, G., Kündgen, A., Gattermann, N., Haas, R., Germing, U.

“…•The IPSS-R is validated as a prognostic tool for patients with MDS and del(5q).•Isolated del(5q) plus one non-chromosome 7 aberration deteriorates the…”
Get full text

P532: ACUTE MYELOID LEUKEMIA (AML): UNICENTRIC REPORT ON 1029 PATIENTS DIAGNOSED IN TERTIAL REFERAL CENTER by Fricke, A., Nachtkamp, K., Döhner, K., Hildebrandt, B., Betz, B., Rudelius, M., Seidl, M., Zahner, C., Kobbe, G., Kündgen, A., Jäger, P. S., Baermann, B.‐N., Germing, U.

Get full text